Folger Nolan Fleming Douglas Capital Management Inc. Sells 4,687 Shares of Pfizer Inc. $PFE

Folger Nolan Fleming Douglas Capital Management Inc. cut its position in shares of Pfizer Inc. (NYSE:PFE) by 21.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 17,188 shares of the biopharmaceutical company’s stock after selling 4,687 shares during the quarter. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in Pfizer were worth $417,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of PFE. Pacer Advisors Inc. boosted its position in Pfizer by 856.8% during the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock valued at $508,164,000 after purchasing an additional 17,957,928 shares during the last quarter. Amundi boosted its position in Pfizer by 43.4% during the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after purchasing an additional 15,758,846 shares during the last quarter. Nuveen LLC acquired a new position in Pfizer during the first quarter valued at approximately $389,861,000. Goldman Sachs Group Inc. boosted its position in Pfizer by 51.9% during the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock valued at $670,407,000 after purchasing an additional 9,041,990 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Pfizer by 0.9% during the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock valued at $13,257,004,000 after purchasing an additional 4,629,976 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

NYSE:PFE opened at $24.81 on Friday. The stock has a market cap of $141.03 billion, a P/E ratio of 13.19, a PEG ratio of 0.83 and a beta of 0.55. The stock has a 50 day simple moving average of $24.86 and a 200 day simple moving average of $24.14. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $29.82.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is 91.49%.

Analyst Ratings Changes

PFE has been the subject of a number of recent analyst reports. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Bank of America raised their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. UBS Group reaffirmed a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday. Finally, Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus price target of $28.35.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.